DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2013/02254.12 A1 Sardari Lodriche Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2013/02254.12 A1 Sardari Lodriche Et Al US 20130225412A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/02254.12 A1 Sardari Lodriche et al. (43) Pub. Date: Aug. 29, 2013 (54) SILICON NANOCARRIER FOR DELIVERY A613 L/702 (2006.01) OF DRUG, PESTICIDES AND HERBICIDES, A6IP3 L/10 (2006.01) AND FOR WASTE WATER TREATMENT A6IP3/04 (2006.01) A6IP35/00 (2006.01) (76) Inventors: Soroush Sardari Lodriche, Tehran (IR): AOIP3/00 (2006.01) Saeed Soltani, Tehran (IR); Roghieh AOIPI3/00 (2006.01) Mirzazadeh, Tehran (IR) BOI 20/22 (2006.01) AOIN 25/08 (2006.01) (21) Appl. No.: 13/406,538 (52) U.S. Cl. USPC ........... 504/322:504/358:504/326; 514/394; (22) Filed: Feb. 28, 2012 514/383: 514/177: 514/274: 514/254.07; 514/110: 514/197; 514/165; 514/253.08: Publication Classification 514/21.1: 514/31; 514/343; 514/61; 424/400; 252/18O (51) Int. Cl. A6 IK9/00 (2006.01) (57) ABSTRACT AOIN37/22 (2006.01) The various embodiments herein provide a nano silicon car AOIN33/06 (2006.01) rier as a drug delivery mechanism. The nano silicon carrier AOIN 43/32 (2006.01) comprises a diatom frustules loaded with a drug molecule to AOIN 43/653 (2006.01) be released at the target site. The diatom frustules are of A 6LX3/57 (2006.01) Hannaea arcus and Navicula inflexia species of diatom. The A6 IK3I/53 (2006.01) pore size of the diatom frustules is 1 to 100 nm. The diatom A6 IK3I/496 (2006.01) frustules are comb-like in structure. The diatom frustules are A6 IK3I/496 (2006.01) in the form of powdered diatomaceous earth. The drug deliv A6 IK3I/664 (2006.01) ery mechanism described in the embodiments herein is a A6 IK3I/43 (2006.01) controlled release mechanism. The nano silicon carrier A6 IK3I/66 (2006.01) described in the embodiments herein is also used for delivery A6 IK38/2 (2006.01) of pesticides and herbicides in plants. The nano silicon carrier A6 IK3I/7048 (2006.01) described in the embodiments herein is also used in hormone A6 IK3 L/46.5 (2006.01) Waste Water treatment. S. S.8 S. S. S. S. S. S. S. S. S.S S. S.S S. S. S. S. S. S. R. S. R. S. R. S. S.& S. S. S. S. S. S. S. S. S. R.S. S. & S.S Patent Application Publication Aug. 29, 2013 Sheet 1 of 9 US 2013/0225412 A1 102 101 FIG. 1 Patent Application Publication Aug. 29, 2013 Sheet 2 of 9 US 2013/0225412 A1 .- FIG. 2A Patent Application Publication Aug. 29, 2013 Sheet 3 of 9 US 2013/0225412 A1 FIG. 2B Patent Application Publication Aug. 29, 2013 Sheet 4 of 9 US 2013/0225,412 A1 FIG. 3 Patent Application Publication Aug. 29, 2013 Sheet 5 of 9 US 2013/0225412 A1 FIG. 4 Patent Application Publication Aug. 29, 2013 Sheet 6 of 9 US 2013/0225412 A1 Release Pattern of Benomy Measured By Nano Drop 38 - 0.3 s S:R S. 0.25 s sS & & S O.2 k's S s S S. 8.5 S. SS. S 0.1 S. s S. &^s. S. S.X S. S X SS' S i. s & S. {} $8x^- : - - - - - - - - - - - - - - - - - - - - - - - - - - - : - - - - - - - - - - - - - - - - - - - - - - - - - - - : - - - - - - - - - ŠssŠ-:- -0.059 3. 3. Sh 8) Time (h) FIG.S Patent Application Publication Aug. 29, 2013 Sheet 7 of 9 US 2013/0225412 A1 Release Patter of S-F Measured By Natio trap 8.2 : s^ : s ^ 3,3S :: s YSSn s 8.1 S N i : 8.85 s : S S 8 iss-s-s-s-s-s-s-sŠss .. ...s. Ms.,...s.. ...x...S. s.s...w.......... Ms. ...x...S. s.s...s..... s.s.. } S 38 3S 2S 3. -3.3s Patent Application Publication Aug. 29, 2013 Sheet 8 of 9 US 2013/0225412 A1 Reiease Patters; a Pragest rats yieasired. By Nana tra 8,38 : s S Š 8.33 S Y.s S. 8.32 & S.S. 83 S.S. Saxx s S. S sS SSS- ^ssašS s 8.88 s y S. S S.& 3.88 S. 8.32 Patent Application Publication Aug. 29, 2013 Sheet 9 of 9 US 2013/0225412 A1 Probit Transformed Responses r O 1000 2000 3000 4000 5000 VAROOOO1 FIG. 8 US 2013/02254.12 A1 Aug. 29, 2013 SILICON NANOCARRIER FOR DELVERY could have a regular specificity of a drug release pattern, OF DRUG, PESTICIDES AND HERBICIDES, which would be extremely useful for nano drug delivery, AND FOR WASTE WATER TREATMENT especially in the cancer treatments. 0012. The evaluation of loading molecules or compounds BACKGROUND into nano-carrier includes some parameters. Previously, some 0001 1. Technical Field useful parameters like molecular weight, number and per 0002 The embodiments herein generally relate to a field centage of nitrogen and oxygen atoms, polarizability (cm), of drug delivery systems and particularly to a drug delivery monoisotopic mass (Da), density (g/cm), nominal mass system using silicon nano vehicle or carrier and more particu (Da), Surface tension (dyne/cm), index of refraction, molar larly to a drug delivery system using diatoms as drug delivery volume (cm), molar refractivity (cm), hydration energies vehicles or carriers. (Kcal/mol), average mass (Da), parachor (cm) and the log 0003 2. Description of the Related Art base 10 of parachor (Log P) have been measured. These 0004. The desired loading and release properties for drug physio-chemical properties have been previously shown to be delivery could be achieved through a selection of appropriate best in describing the controlling factors for loading drugs. systems and drug molecules. The designing of Such new 0013 But no work has been done in using these diatoms carriers for drug delivery is an important field of research. for delivering the drugs efficiently at the target site. Hence the Nanotechnology as one of the new and latest fields of tech embodiments herein provide the use of diatoms as nano drug nology can help us to use naturally occurring structures in delivery carrier for the delivery of drugs at their target sites. designing a new type of drug vehicles using diatoms. The Also the embodiments herein provide the use of diatoms in diatoms are unicellular microalgae. the field of agriculture and wastewater treatment. 0005 Diatoms belong to Chrysophyta division, Bacillari 0014. The above mentioned shortcomings, disadvantages ophaceae class with a cell wall consisting of a siliceous skel and problems are addressed herein and which will be under eton or Frustule enveloped by an organic case essentially stood by reading and studying the following specification. composed of polysaccharides and proteins. Diatoms as a group are very diverse in nature, comprising some 12,000 OBJECTIVES OF THE EMBODIMENTS 60,000 reported species and a common diameter of 20-200 0015 The primary object of the embodiments herein is to microns. Diatoms are divided into two broad groups: centric provide a novel drug delivery system using diatoms. and pinnate, depending on the symmetry of frustules. All 0016. Another object of the embodiments herein is to pro diatoms have, parallel striates or furrows or rows of holes, in vide a nano drug delivery system using diatom frustules for the silica arranged normal to the structural axis. The spacing various applications. between the adjacent striate is species specific, but typically 0017. Yet another object of the embodiments herein is to varies from 0.3 to 2 um. The line of silica between the striate provide a nano drug delivery system made up of siliceous is called costae. Costae tend to be symmetrically arranged in diatomaceous structure for delivering various pharmaceutical combs or other space filling patterns. drugs in humans and animals. 0006. In the recent years some attempts have been made to 0018 Yet another object of the embodiments herein is to use frustules in nanotechnology applications. Some provide a nano drug delivery system that can be used for researches in this field are as follows: delivering agricultural drugs and pesticides. 0007 Immuno-isolation and immunological bio-encapsu lation could benefit from the frustule properties. The key 0019. Yet another object of the embodiments herein is to feature of such capsules would be the ability of frustule pores provide a nano drug delivery system that can be used for to protect the enclosed tissue from immune rejection while delivering anticancer drugs. allowing an adequate Supply of nutrients and oxygen. One 0020. Yet another object of the embodiments herein is to possible drawback could be the immune reactivity of the provide a nano drug delivery system that can be used for silica itself. treating the fungal infections in humans. 0021. Yet another object of the embodiments herein is to 0008 Microfabrication: diatom frustules have potential provide a nano drug delivery system that can be used for the use in the production of nanomaterials of constant diameter. removal of hormonal waste from wastewater and industrial For example, using a template synthesis method, it may be Sewage. possible to arrange these pores to form nanometer sized tubes 0022. These and other objects and advantages of the and/or fibers. embodiments herein will become readily apparent from the 0009 Lithographic applications: using the costae of pin following detailed description taken in conjunction with the nate diatoms as a mask in the lithographic process led to the accompanying drawings. formation of parallel array of uniform channels. Use of cen tric diatoms, for which their exposed surface is resistant to the etching process, leads to a formation of radiating channels. SUMMARY 0010 Magnetized frustules for pinpoint drug delivery: to 0023 The various embodiments herein provide a nano produce magnetized frustules, diatoms can be cultured in an silicon carrier made up of diatom frustules that can be loaded iron-rich environment, as described by Wee et al.
Load more

Recommended publications
  • Synthesis, Physicochemical Characterization and Study of the Antimicrobial Activity of Chlorobutanol H
    World Academy of Science, Engineering and Technology International Journal of Pharmacological and Pharmaceutical Sciences Vol:12, No:3, 2018 Synthesis, Physicochemical Characterization and Study of the Antimicrobial Activity of Chlorobutanol H. Nadia, G. Bahdja, S. Thili Malha, Y. Zahoua, D. Taoufik, B. Mourad, M. Marzouk, F. Z. Hadjadj Aoul, L. R. Mekacher I. INTRODUCTION Abstract—Introduction and objectives: Chlorobutanol is a raw XCIPIENTS play a vital role in the design, manufacture material, mainly used as an antiseptic and antimicrobial preservative and preservation of drugs. The addition of an in injectable and ophthalmic preparations. The main objective of our E study was the synthesis and evaluation of the antimicrobial activity of antimicrobial agents is of great interest in the case where the chlorobutanol hemihydrates. Material and methods: Chlorobutanol pharmaceutical preparations do not have adequate was synthesized according to the nucleophilic addition reaction of antimicrobial properties, (especially aqueous preparations), to chloroform to acetone, identified by an infrared absorption using prevent proliferation or limit microbial contamination [1], [2]. Spectrum One FTIR spectrometer, melting point, Scanning electron Chlorobutanol is a trihalogen alcohol with bacteriostatic and microscopy and colorimetric reactions. The dosage of Carvedilol fungistatic activity. The main objective of our work was to active substance was carried out by assaying the degradation products of chlorobutanol in a basic solution. The chlorobutanol obtained was obtain chlorobutanol hemihydrate by chemical synthesis, its subjected to bacteriological tests in order to study its antimicrobial purification and characterization as well as the study of its activity. The antibacterial activity was evaluated against strains such antimicrobial activity. as Escherichia coli (ATCC 25 922), Staphylococcus aureus (ATCC 25 923) and Pseudomonas aeroginosa (ATCC = American type II.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • CAS No.) Screening Justification Is Public Comment Now Open? CAS No
    EGLE Air Quality Division (AQD) Air Toxics Screening Level Justifications (Numerically by CAS No.) Screening Justification Is Public Comment Now Open? CAS No. Chemical Name Level & Responses Info E-Mail AQD Deadline None ad acid View View Not Open for Public Comment None amyl acetate (mixture) View View Not Open for Public Comment None atlox 848 View View Not Open for Public Comment None biosam tp-1.5 View View Not Open for Public Comment None calcium chloride View View Not Open for Public Comment None epoxy resin solution View View Not Open for Public Comment None heptamethyl-1-vinyl-1,7-dichlorotetrasilazane View View Not Open for Public Comment None n-butylglucamine View View Not Open for Public Comment None n-chloro-2,6-difluorobenzamide View View Not Open for Public Comment None trichloroethylene View View Not Open for Public Comment None triethylammonium suleptanate View View Not Open for Public Comment 50-00-0 formaldehyde View View Not Open for Public Comment 50-03-3 hydrocortisone acetate View View Not Open for Public Comment 50-21-5 lactic acid View View Not Open for Public Comment 50-28-2 estradiol View View Not Open for Public Comment 50-29-3 ddt View View Not Open for Public Comment 50-32-8 benzo(a)pyrene View View Not Open for Public Comment 51-28-5 2,4-dinitrophenol View View Not Open for Public Comment 53-36-1 methyl predisolone acetate View View Not Open for Public Comment 53-70-3 dibenz(a,h)anthracene View View Not Open for Public Comment 56-23-5 carbon tetrachloride View View Not Open for Public Comment 56-49-5 3-methylcholanthrene View View Not Open for Public Comment 56-55-3 benz(a)anthracene View View Not Open for Public Comment 56-81-5 glycerol View View Not Open for Public Comment 57-11-4 stearic acid View View Not Open for Public Comment Revised Monday, September 27, 2021 Page 1 of 51 EGLE Air Quality Division (AQD) Air Toxics Screening Level Justifications (Numerically by CAS No.) Screening Justification Is Public Comment Now Open? CAS No.
    [Show full text]
  • Guide to Extractables in Effluents from Ultipor® N66 and Posidyne® Filter
    Validation Guide USTR 2521 Guide to Extractables in Effluents from Pall Ultipor ® N66 and Posidyne ® Filter Cartridges Contents 1. Introduction ........................................................................................................................3 2. Design and Manufacture of Pall N66 Pharmaceutical-rated (P-rated) Filters ................3 3. Principles of Extraction and the Non-Volatile Residue Test ............................................3 3.1 Factors Limiting Extraction ............................................................................................3 3.2 Defining Solvent Strength ..............................................................................................4 3.3 Materials of Construction of Ultipor N66 and Posidyne Filter Cartridges ........................5 3.4 Extractable Substances in Polymers Used in Pall Ultipor N66 and Posidyne Filter Cartridges ....................................................................................................5 4. Total Non-volatile Residues Extracted from Ultipor N66 and Posidyne Filters ..............6 4.1 Introduction ....................................................................................................................6 4.2 Summary of Method ......................................................................................................6 4.3 Results ..........................................................................................................................6 4.4 Conclusions ..................................................................................................................6
    [Show full text]
  • United States Patent Office Patented Aug
    2,760,990 United States Patent Office Patented Aug. 28, 1956 acid. If an acid group other than acetate is desired, mercury acetate and higher boiling carboxylic acid may 2,760,990 be intimately mixed together and the mixture is taken VNY TRANSETHERFICATION up with the starting vinyl ether. At this point the 5 mixture may be heated with stripping off of acetic acid. Warren H. Watanabe, Philadelphia, Pa., and Lawrence The reacting alcohol is then added and the mixture heated. E. Conlon, Moorestown, N.J., assignors to Rohm & Alternatively mercury acetate, carboxylic acid, vinyl Haas Company, Philadelphia, Pa., a corporation of ether, and alcohol are mixed and heated. Acetic acid Delaware may now be distilled off. The preparation of catalyst in No Drawing. Application August 15, 1952, O these ways, gives a highly active material, effective even Serial No. 304,648 at elevated temperatures. Another method of forming transetherifying catalysts 9 Claims. (C.260-614) is to mix together a common mercury salt of a strong acid, such as mercuric sulfate, and an alkali metal salt This invention concerns a process for preparing vinyl 5 of a desired carboxylic acid. Thus mercuric sulfate may ethers by transetherifying other vinyl ethers with alcohols be mixed with sodium oleate, or sodium benzoate, or in the presenec of soluble mercury salts of weak acids. It sodium ethylbutyrate. Such mixtures simulate the mer also deals with novel vinyl ethers, cury salts of weak acids, although they still give consid It has been proposed that volatile vinyl alkyl ethers erable acetal formation. in which the alkyl group is primary be reacted with pri 20 When alcohols are used which are acid sensitive, or mary or secondary monohydric alcohols: consisting of which are unstable to acid, or which decompose to give.
    [Show full text]
  • Papaverine Hydrochloride Injection, Solution American Regent, Inc
    PAPAVERINE HYDROCHLORIDE- papaverine hydrochloride injection, solution American Regent, Inc. Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here. ---------- PAPAVERINE HYDROCHLORIDE INJECTION, USP Rx Only This product is to be used by or under the direction of a physician. Each vial contains a sufficient amount to permit withdrawal and administration of the volume specified on the label. DESCRIPTION Papaverine Hydrochloride, USP, is the hydrochloride of an alkaloid obtained from opium or prepared synthetically. It belongs to the benzylisoquinoline group of alkaloids. It does not contain a phenanthrene group as do morphine and codeine. Papaverine Hydrochloride, USP, is 6,7-dimethoxy-1- veratrylisoquinoline hydrochloride and contains, on the dried basis, not less than 98.5% of C20H21NO4•HCI. The molecular weight is 375.85. The structural formula is as shown. Papaverine Hydrochloride occurs as white crystals or white crystalline powder. One gram dissolves in about 30 mL of water and in 120 mL of alcohol. It is soluble in chloroform and practically insoluble in ether. Papaverine Hydrochloride Injection, USP, is a clear, colorless to pale-yellow solution. Papaverine Hydrochloride, for parenteral administration, is a smooth-muscle relaxant that is available in vials containing 30 mg/mL. Each vial also contains edetate disodium 0.005%. The 10 mL vials also contain chlorobutanol 0.5% as a preservative. pH may be adjusted with sodium citrate and/or citric acid. CLINICAL PHARMACOLOGY The most characteristic effect of papaverine is relaxation of the tonus of all smooth muscle, especially when it has been spasmodically contracted.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Safety Data Sheet - Version 5.0 Preparation Date 5/8/2017 Latest Revision Date (If Revised) 2/24/2021 SDS Expiry Date 2/23/2024
    Safety Data Sheet - Version 5.0 Preparation Date 5/8/2017 Latest Revision Date (If Revised) 2/24/2021 SDS Expiry Date 2/23/2024 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING 1.1 Product Identifier Chemical Name Chlorbutanol Hemihydrate Catalogue # C364795 1.2 Relevant Identified Uses of the Substance or Mixture and Uses Advised Against Product Uses To be used only for scientific research and development. Not for use in humans or animals. 1.3 Details of the Supplier of the Safety Data Sheet Company Toronto Research Chemicals 2 Brisbane Road Toronto, ON M3J 2J8 CANADA Telephone +14166659696 FAX +14166654439 Email [email protected] 1.4 Emergency Telephone Number Emergency# +1(416) 665-9696 between 0800-1700 (GMT-5) 2. HAZARDS IDENTIFICATION 2.1/2.2 Classification of the Substance or Mixture and Label Elements GHS Hazards Classification (According to EU Regulation 1272/2008 and US OSHA 1910.1200) Acute Toxicity, Oral (Category 4) GHS Hazards Identification (According to EU Regulation 1272/2008 and US OSHA 1910.1200) Signal Word Warning GHS Hazard Statements H302 Harmful if swallowed. GHS Precautionary Statements P264 Wash hands thoroughly after handling. P270 Do no eat, drink or smoke when using this product. P301/P312 IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. P330 Rinse mouth. 2.3 Unclassified Hazards/Hazards Not Otherwise Classified No data available. 3. COMPOSITION/INFORMATION ON INGREDIENTS 3.1 Substances Molecular Formula: C4H7Cl3O•0.5[H2O] Molecular Weight: 177.46 [Anhydrous]
    [Show full text]
  • Mar. Biol. Ass. India, 1965, 8 (1): 28-56 EFFECTS OF
    /. Mar. biol. Ass. India, 1965, 8 (1): 28-56 EFFECTS OF ANAESTHETICS ON THE BEHAVIOUR OF MULLET FINGERLINGS AND THE SCOPE OF USING THESE IN DIFFERENT FISHERY PROCEDURES-!* By V. S. DURVE** AND S. K. DHARMA RAJA Central Marine Fisheries Research Institute, Mandapam Camp INTRODUCTION THE use of anaesthetics in fishery work, mainly in the transport of live-fish and also in handling fish for tagging, fin-clipping, weighing and stripping has been recognised by fishery workers everywhere. In live-fish transport, anaesthetics are useful in lowering the metabolic activity of fish, which facilitates the transport of more fish in a given quantity of water for a longer time. It has also been proved that anaes­ thetics make the otherwise time consuming work of tagging and fin-clipping much easier and also lower the mortality of the fish due to handling. Considerable effort has gone into a search for a proper anaesthetic and its different concentrations to give varying degrees of anaesthesia useful for works from tagging to transport of live-fish. Several methods have been used to produce anaesthesia. Abramowitz (1937), Parker (1937, 1939), Abramowitz et al. (1940) Osborn (1938, 1941) immersed fishes in crushed ice or ice water. Haskell (1940) employed electric shock to produce a paralysis lasting about two minutes. It is doubtful whether the anaesthesia induced by these methods is similar to that induced by chemicals. The disadvantages of such methods have been discussed by Pickford and Atz (1957). Chemicals used to anaesthetize fishes include Ether, Urethane, Chlorobutanol, MS-222 SANDOZ, Sodium Amytal and Chloral Hydrate, besides 8 to 9 others.
    [Show full text]
  • Administrative Records, Texas Department of Criminal Justice
    Consistent with the terms of the Court’s May 22, 2017 scheduling order, the record has been redacted for all information that plaintiff, Texas Department of Criminal Justice (Texas), has identified as confidential. In addition, Defendants have also redacted information that the drug’s supplier and broker have separately advised the agency they consider confidential and private, as well as information the agency itself generally treats as confidential. This information has been redacted pending final FDA’s review of confidentiality claims, and our filing of the record with these redactions does not necessarily reflect our agreement with all of the claims of confidentiality Defendants have received. Defendants explicitly reserve the right to make an independent determination regarding the proper scope of redactions at a later time. Should we identify any of Texas’s redactions that are over-broad or otherwise improper, we will work with Texas’s counsel to revise the redactions in the record. MISCELLANEOUS FDA 568 DOCUMENT#: VERSION#: DIOP PROCEDURE ~L ORO-DIOP- 2.00 FOOD & DRUG ADMINISTRATION .008 I OFFICE OF REGULATORY AFFAIRS PAGE 1 OF 4 TITLE: EFFECTIVE DATE: PROCESSING OF SODIUM THIOPENTAL ENTRIES 4/16/2012 Sections included in this document 1. Purpose 2. Scope 3. Responsibility 4. Background 5. References 6. Procedure 7. Definitions/Glossary 8. Records 9. Supporting Documents 10. Contact Information 11.Attachments Document History and Change History 1. Purpose Pending litigation, this procedure provides instructions on the handling of shipments of Sodium Thiopental by Districts and the responsibility of DIOP in the processing of Sodium Thiopental entries. Districts should disseminate this information to all pertinent staff handling these entries.
    [Show full text]
  • Material Safety Data Sheet
    Material Safety Data Sheet 1,1,1-Trichloro-2-methyl-2-propanol hemihydrate ACC# 96913 Section 1 - Chemical Product and Company Identification MSDS Name: 1,1,1-Trichloro-2-methyl-2-propanol hemihydrate Catalog Numbers: AC150300000, AC150305000, AC421560000, AC421561000, AC421565000 Synonyms: beta,beta,beta-Trichloro-tert-butyl alcohol hemihydrate; Trichloro-tert-butanol hemihydrate; Acetone chloroform hemihydrate; Chlorobutanol; Chloretone (Parke, Davis); Coliquifilm (Allergan); Methaform; Sedaform. Company Identification: Acros Organics N.V. One Reagent Lane Fair Lawn, NJ 07410 For information in North America, call: 800-ACROS-01 For emergencies in the US, call CHEMTREC: 800-424-9300 Section 2 - Composition, Information on Ingredients CAS# Chemical Name Percent EINECS/ELINCS 6001-64-5 1,1,1-Trichloro-2-methyl-2-propanol hemihydrate 98 unlisted Section 3 - Hazards Identification EMERGENCY OVERVIEW Appearance: white powder. Caution! May cause eye, skin, and respiratory tract irritation. May be harmful if swallowed. Target Organs: No data found. Potential Health Effects Eye: May cause eye irritation. Skin: May cause skin irritation. Ingestion: May cause irritation of the digestive tract. May be harmful if swallowed. Inhalation: May cause respiratory tract irritation. Chronic: No information found. Mouse experiments in one lab indicated that this agent may be transferred across the placenta. In vitro culture of mouse embryos has produced abnormal development with concentrations of 25 mcg/ml or above. Although human serum concentrations of this agent have not been well characterized, there are reports of patients on chronic therapy with chlorobutanol- containing medications who had serum concentrations of 50 - 85 mcg/ml. The serum concentration after a single 600 mg oral dose of chlorobutanol was 4-5 mcg/ml.
    [Show full text]
  • 201 PART 329—HABIT-FORMING DRUGS Subpart A—Derivatives
    Food and Drug Administration, HHS § 329.1 section 502(e) of the Federal Food, PART 329ÐHABIT-FORMING DRUGS Drug, and Cosmetic Act. (d) The statement expressing the Subpart AÐDerivatives Designated as amount (percentage) of alcohol present Habit Forming in the product shall be in a size reason- ably related to the most prominent Sec. printed matter on the panel or label on 329.1 Habit-forming drugs which are chem- which it appears, and shall be in lines ical derivatives of substances specified in generally parallel to the base on which section 502(d) of the Federal Food, Drug, the package rests as it is designed to be and Cosmetic Act. displayed. (e) For a product to state in its label- Subpart BÐLabeling ing that it is ``alcohol free,'' it must 329.10 Labeling requirements for habit- contain no alcohol (0 percent). forming drugs. (f) For any OTC drug product in- tended for oral ingestion containing Subpart CÐExemptions over 5 percent alcohol and labeled for use by adults and children 12 years of 329.20 Exemption of certain habit-forming age and over, the labeling shall contain drugs from prescription requirements. the following statement in the direc- AUTHORITY: 21 U.S.C. 352, 353, 355, 371. tions section: ``Consult a physician for use in children under 12 years of age.'' SOURCE: 39 FR 11736, Mar. 29, 1974, unless (g) For any OTC drug product in- otherwise noted. tended for oral ingestion containing over 0.5 percent alcohol and labeled for Subpart AÐDerivatives use by children ages 6 to under 12 years Designated as Habit Forming of age, the labeling shall contain the following statement in the directions § 329.1 Habit-forming drugs which are section: ``Consult a physician for use in chemical derivatives of substances children under 6 years of age.'' specified in section 502(d) of the (h) When the direction regarding age Federal Food, Drug, and Cosmetic in paragraph (e) or (f) of this section Act.
    [Show full text]